- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05722418
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage)
April 8, 2024 updated by: Caribou Biosciences, Inc.
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Caribou Biosciences
- Phone Number: 3 510-982-6030
- Email: clinicaltrials@cariboubio.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Luciano Costa, MD
- Phone Number: 205-975-3371
- Email: ljcosta@uabmc.edu
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics
-
Contact:
- Jay Spiegel, MD
- Phone Number: 305-243-0372
- Email: Spiegelj@med.miami.edu
-
Principal Investigator:
- Jay Spiegel, MD
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky/ Markey Cancer Center
-
Contact:
- Ashley Walton-Robbins
- Phone Number: 589-218-1758
- Email: Ashley.robbins@uky.edu
-
Principal Investigator:
- Gregory Monohan, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 220071
- Recruiting
- Massachusetts General
-
Contact:
- Andrew Branagan, MD
- Phone Number: 617-724-4000
- Email: abranagan@mgh.harvard.edu
-
Principal Investigator:
- Andrew Branagan, MD
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- John Theurer Cancer Center At Hackensack UMC
-
Contact:
- Palka Anand
- Phone Number: 551-996-8704
- Email: Palka.anand@hmhn.org
-
Principal Investigator:
- David Siegal, MD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Sham Mailankody, MBBS
- Phone Number: 646-608-2091
- Email: cart@mskcc.org
-
Principal Investigator:
- Sham Mailankody, MBBS
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Adriana Rossi, MD
- Phone Number: 917-828-3905
- Email: adriana.rossi@mssm.edu
-
Principal Investigator:
- Adriana Rossi, MD
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Levine Cancer Institute
-
Contact:
- Kelly Bumgarner
- Email: Kelly.Bumgarner@atriumhealth.org
-
Principal Investigator:
- Manisha Bhutani, MD
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University Health System (DUHS)
-
Principal Investigator:
- Cristina Gasparetto, MD
-
Contact:
- Matthew Fisher
- Phone Number: 919-668-1028
- Email: Matthew.Fister@Duke.edu
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
- Recruiting
- Oncology Hematology Care, Inc
-
Contact:
- Doug Hart
- Email: douglas.hart@usoncology.com
-
Principal Investigator:
- James Essell, MD
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Phone Number: 216-444-7923
- Email: Canceranswer@ccf.org
-
Principal Investigator:
- Faiz Anwer, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Active, not recruiting
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
Principal Investigator:
- Neeraj Saini, MD
-
Contact:
- Shiny Jayan
- Phone Number: 832-438-7390
- Email: sjayan@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute, University of Utah
-
Principal Investigator:
- Douglas Sborov, MD
-
Contact:
- Collind Boyington
- Phone Number: 801-587-4779
- Email: collind.boyington@HCI.UTAH.EDU
-
-
Virginia
-
Richmond, Virginia, United States, 23235
- Recruiting
- Virginia Commonwealth University
-
Contact:
- Johanna Biamonte
- Phone Number: 804-628-1896
- Email: jbiamonte@vcu.edu
-
Principal Investigator:
- William Clark, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert and The Medical College of Wisconsin
-
Principal Investigator:
- Binod Dhakal, MD
-
Contact:
- Danielle King
- Phone Number: 414-805-9334
- Email: daking@mcw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)
- Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody as part of a prior line of therapy, either in monotherapy or in combination.
- Eastern Cooperative Oncology Group performance status grade of 0 or 1.
- Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.
Exclusion Criteria:
- Prior treatment with CAR-T cell therapy directed at any target.
- Autologous stem cell transplant within the last 6 weeks before lymphodepletion.
- Allogeneic stem cell transplant within 6 months before lymphodepletion.
- Known active or prior history of CNS involvement.
- Stroke or seizure within 6 months of signing ICF.
- Seropositive for or history of human immunodeficiency virus.
- Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion.
- Hepatitis B infection.
- Hepatitis C infection.
- Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or its excipients.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CB-011
|
CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(Part A) Number of patients with dose limiting toxicities (DLT)
Time Frame: 28 days
|
Number of patients with DLTs during the 28 days following the first administration of CB-011.
|
28 days
|
(Part B) Overall Response Rate (ORR)
Time Frame: 12 Months
|
The ORR will be evaluated by International Myeloma Working Group (IMWG) criteria.
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 6, 2023
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
December 19, 2022
First Submitted That Met QC Criteria
February 2, 2023
First Posted (Actual)
February 10, 2023
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- CB11A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Multiple Myeloma
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
Carl Ola Landgren, MD, PhDBristol-Myers SquibbRecruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...CompletedMultiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Ionis Pharmaceuticals, Inc.Active, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
Clinical Trials on CB-011
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
Nexel Co., Ltd.Novotech (Australia) Pty LimitedCompleted
-
Hutchison Medipharma LimitedCompletedInflammatory Bowel Diseases
-
AbbVieCompletedSmall Cell Lung CancerUnited States, Japan, Korea, Republic of, Taiwan
-
University of MinnesotaRecruitingCannabis Use DisorderUnited States
-
CymaBay Therapeutics, Inc.Completed
-
Orionis Biosciences IncRecruiting
-
CelgeneCelgene CorporationTerminatedAdvanced Solid TumorsUnited States
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States